Health Care [ 8/12 ] | Biotechnology [ 27/73 ]
NASDAQ | Common Stock
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.
The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.
In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration.
Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain.
The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system.
MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.51 Decreased by -59.38% | -0.50 Decreased by -2.00% |
| Mar 12, 25 | -0.50 Decreased by -19.05% | -0.56 Increased by +10.71% |
| Nov 12, 24 | -0.55 Increased by +25.68% | -0.52 Decreased by -5.77% |
| Aug 12, 24 | -0.76 Decreased by -43.40% | -0.40 Decreased by -90.00% |
| May 9, 24 | -0.32 Increased by +48.39% | -0.50 Increased by +36.00% |
| Mar 14, 24 | -0.42 Increased by +30.00% | -0.11 Decreased by -281.82% |
| Nov 14, 23 | -0.74 Increased by +10.84% | -0.55 Decreased by -34.55% |
| Aug 10, 23 | -0.53 Increased by +30.26% | -0.57 Increased by +7.02% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 1.93 M Increased by +176.33% | -39.98 M Decreased by -95.58% | Decreased by -2.08 K% Increased by +29.22% |
| Dec 31, 24 | 21.39 M Increased by +948.53% | -39.40 M Decreased by -294.90% | Decreased by -184.19% Decreased by -118.59% |
| Sep 30, 24 | 10.91 M Increased by +113.80% | -39.33 M Increased by +11.21% | Decreased by -360.49% Increased by +58.47% |
| Jun 30, 24 | 282.00 K Decreased by -92.03% | -48.62 M Decreased by -64.36% | Decreased by -17.24 K% Decreased by -1.96 K% |
| Mar 31, 24 | 697.00 K Decreased by -79.09% | -20.44 M Increased by +36.17% | Decreased by -2.93 K% Decreased by -205.30% |
| Dec 31, 23 | 2.04 M Increased by +138.58% | 20.21 M Increased by +248.96% | Increased by +990.93% Increased by +286.12% |
| Sep 30, 23 | 5.10 M Increased by +5.96% | -44.30 M Increased by +14.42% | Decreased by -868.06% Increased by +19.23% |
| Jun 30, 23 | 3.54 M Decreased by -67.10% | -29.58 M Increased by +12.93% | Decreased by -835.62% Decreased by -164.64% |